1194018-16-0Relevant articles and documents
Identification of novel azaindazole CCR1 antagonist clinical candidates
Harcken, Christian,Kuzmich, Daniel,Cook, Brain,Mao, Can,Disalvo, Darren,Razavi, Hossein,Swinamer, Alan,Liu, Pingrong,Zhang, Qiang,Kukulka, Alison,Skow, Donna,Patel, Mita,Patel, Monica,Fletcher, Kimberly,Sherry, Tara,Joseph, David,Smith, Dustin,Canfield, Melissa,Souza, Donald,Bogdanffy, Matthew,Berg, Karen,Brown, Maryanne
, p. 441 - 448 (2019/01/04)
Exploring various cyclization strategies, using a submicromolar pyrazole HTS screening hit 6 as a starting point, a novel indazole based CCR1 antagonist core was discovered. This report presents the design and SAR of CCR1 indazole and azaindazole antagonists leading to the identification of three development compounds, including 19e that was advanced to early clinical trials.
INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
-
Page/Page column 55-56, (2009/12/05)
Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
